Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients

Exclusion criteria

• . Severely ill patients who meet the following criteria:
• . Uncontrolled pulmonary diseases other than COVID-19 pneumonia (ex. chronic obstructive pulmonary disease, asthma, cystic fibrosis, tuberculosis, etc.)
• . Patients requiring intubation, mechanical ventilation (WHO 8-OS stage 6), or ECMO (stage 7) at the time of screening.
• . Individuals who have received treatment with ATG (Antithymocyte Globulin), Campath, or other T-cell immunosuppressive monoclonal antibodies within 28 days prior to the screening visit.
• . Patients with uncontrollable hypertension, uncontrollable diabetes, other viral infections (ex. Human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), etc), syphilis, refractory malignancy, moderate or severe liver damage \[Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \> 5 Lab normal range (LNR)\], or chronic kidney diseases (estimated Glomerular filtration rate (eGFR) \< 30 mL/min/1.73m\^2) based on medical history or at the time of screening.
• . Severe hyperglycemia with HbA1c ≥ 10.0%
• . Individuals who have been hospitalized for diabetic ketoacidosis within the past 12 weeks
• . Individuals who have received emergency treatment or been hospitalized within the past 12 weeks for severe hypoglycemia (glucose \< 54mg/dL) accompanied by seizures and loss of consciousness

Characterization of SARS-CoV-2-Specific T cells

Timeframe: From the screening visit through 24 weeks after treatment initiation.